These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32320170)

  • 21. Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism.
    Chan YH; Wu LS; See LC; Liu JR; Chang SH; Chao TF; Yeh YH; Kuo CT; Lee HF; Lip GYH
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32009154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry.
    Sherwood MW; Piccini JP; Holmes DN; Pieper KS; Steinberg BA; Fonarow GC; Allen LA; Naccarelli GV; Kowey PR; Gersh BJ; Mahaffey KW; Singer DE; Ansell JE; Freeman JV; Chan PS; Reiffel JA; Blanco R; Peterson ED; Rao SV
    Circ Cardiovasc Interv; 2020 May; 13(5):e008274. PubMed ID: 32408815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.
    Bhatia HS; Bailey J; Unlu O; Hoffman K; Kim RJ
    Pacing Clin Electrophysiol; 2019 Nov; 42(11):1463-1470. PubMed ID: 31599969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation.
    Briasoulis A; Mentias A; Mazur A; Alvarez P; Leira EC; Vaughan Sarrazin MS
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):261-272. PubMed ID: 33404923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis.
    Casula M; Fortuni F; Fabris F; Leonardi S; Gnecchi M; Sanzo A; Greco A; Rordorf R
    J Cardiovasc Med (Hagerstown); 2020 Aug; 21(8):570-576. PubMed ID: 32628422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study.
    Wang CL; Wu VC; Huang YT; Kuo CF; Chu PH; Chen YL; Wen MS; Chang SH
    J Am Heart Assoc; 2019 May; 8(9):e012029. PubMed ID: 31020896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort Study.
    Søgaard M; Skjøth F; Jensen M; Kjældgaard JN; Lip GYH; Larsen TB; Nielsen PB
    J Am Heart Assoc; 2019 Jun; 8(11):e011358. PubMed ID: 31138001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort.
    Said A; Keeney S; Matka M; Hafeez A; George J; Halalau A
    BMC Cardiovasc Disord; 2020 Jun; 20(1):263. PubMed ID: 32487114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Jackson LR; Kim S; Blanco R; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Kowey PR; Mahaffey KW; Hylek EM; Peterson ED; Piccini JP;
    Am Heart J; 2020 Aug; 226():85-93. PubMed ID: 32526533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing DOAC and warfarin outcomes in an obese population using the 'real-world' Michigan Anticoagulation Quality Improvement Initiative (MAQI
    Ardeshna N; Feldeisen T; Kong X; Haymart B; Kaatz S; Ali M; Barnes GD; Froehlich JB
    Vasc Med; 2024 Oct; 29(5):543-552. PubMed ID: 39177515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
    Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight.
    Lee SR; Choi EK; Park CS; Han KD; Jung JH; Oh S; Lip GYH
    J Am Coll Cardiol; 2019 Mar; 73(8):919-931. PubMed ID: 30819360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
    Alamneh EA; Chalmers L; Bereznicki LR
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Warfarin in Atrial Fibrillation Patients with Prior Stroke: a Systematic Review and Meta-analysis.
    Umashankar K; Mammi M; Badawoud E; Tang Y; Zhou M; Borges JC; Liew A; Migliore M; Mekary RA
    Cardiovasc Drugs Ther; 2023 Dec; 37(6):1225-1237. PubMed ID: 35467313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
    Miao B; Alberts MJ; Bunz TJ; Coleman CI
    J Thromb Thrombolysis; 2019 Oct; 48(3):366-372. PubMed ID: 31228038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.